Results for the first 10 patients offer promising signs for giving patients with multiple myeloma a prophylactic dose of tocilizumab before they are treated with the bispecifc antibody teclistamab.
The first 10 patients with multiple myeloma given a prophylactic dose of tocilizumab prior to treatment with teclistamab have not experienced cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS), according to data from a pilot study presented today at the 2024 annual meeting of the American Society of Clinical Oncology (ASCO).1
Early findings from the OPTec study (NCT05972135) could signal a breakthrough in patients’ ability to receive teclistamab, a bispecific antibody sold as Tecvayli,2 in community settings. More patients could access teclistamab if clinicians could prevent patients from experiencing an adverse event (AE) requiring hospital admission.
Teclistamab is the only FDA-approved therapy with weight-based dosing to target B-cell maturation antigen (BCMA) on multiple myeloma cells and CD3 on T-cells to activate an immune response.2 The therapy has a step-up dosing schedule, which allows some flexibility on when it is administered to deal with CRS or ICANS.
Robert M. Rifkin, MD | Image credit: Rocky Mountain Cancer Centers
The pilot, led by Robert M. Rikfin, MD, medical oncologist/hematologist of Rocky Mountain Cancer Centers of Denver, Colorado, is based on findings from a cohort of the MajesTEC-1 study,3 which led to approval for teclistamab in patients who have received at least 3 therapies for multiple myeloma. CRS was seen in 72% of patients in cycles 1 and 2, with 33% seeing recurrent CRS. However, among a group of patients who had a prophylactic dose of tocilizumab, only 26% of patients had CRS.
The purpose of the pilot is to evaluate whether giving a prophylactic dose of tocilizumab can prevent neurologic AEs when teclistamab is administered in a community setting. This requires carefully following patients to ensure that tocilizumab, normally given at the onset of CRS, does not alter the efficacy of the therapy.
“All of the safety endpoints are early,” cautioned Rifkin, who explained the pilot’s methodology.
This process required investigators to treat 5 patients, present findings to the data review committee (DRC); treat 5 more patients, then present those findings to the DRC. Under the study’s protocol, with the DRC’s blessing, the study can then expand from 4 sites to 12 and enroll an additional 40 patients.
“We’ve completed our first 10 patients,” Rifkin said in an interview. “The next data review committee will be within the next 2 weeks, and we're optimistic we'll be able to then open it up and accrue the remaining 40 patients.”
In addition, he said, “A talquetamab arm will be added,” referencing the bispecific antibody sold as Talvey, which is a GPRC5D-directed CD3 T-cell engager.
Both teclistamab and talquetamab are made by Johnson & Johnson, which sponsored the study with the Sarah Cannon Research Institute.
Rifkin was enthusiastic about the results, but he noted that giving patients teclistamab will still require a community practice to have resources to properly administer the therapy, which is given through subcutaneous injection. Patients must still have a caregiver present, there is still the likelihood of fever, and results show that other AEs such as headaches or nausea remain.
“It’s still a team effort,” Rifkin said. One approach being considered is that after a few weekly doses, patients in the study could return to their local oncologist, because the window for CRS or ICANS to appear will have passed.
Methods. Study protocol call for the following:1
Results: Data presented at ASCO include the following:1
References
The Push for Fair Pricing and Reform in Pharmacy Benefit Management
April 3rd 2025Amid growing legislative pressures and industry debates, pharmacy benefit managers (PBMs) are exploring new strategies to enhance transparency, reduce patient costs, and navigate the evolving healthcare landscape.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Using AI-Driven Strategies to Optimize Specialty Drug Costs, Manage Polypharmacy
April 2nd 2025As health care costs continue to rise, artificial intelligence (AI)-driven solutions are emerging as a powerful tool for managing specialty drug spending and polypharmacy risks, as showcased in recent research presented at the Academy of Managed Care Pharmacy 2025 conference.
Read More
Oncology Onward: A Conversation With Dr Debra Patt of Texas Oncology
August 1st 2023Debra Patt, MD, PhD, MBA, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for episode 2 of our newest podcast, "Oncology Onward: Conversations With Innovators and Changemakers in Cancer Care."
Listen
How Recent Federal Policy Changes Are Shaping Managed Care Pharmacy
April 2nd 2025Federal legislative and regulatory changes are reshaping pharmacy practice, with key challenges in government funding, pharmacy benefit manager reform, and health care policy shifts—topics explored by experts at the Academy of Managed Care Pharmacy's annual meeting.
Read More
The IRA’s Unintended Consequences for Drug Pricing and Coverage
April 2nd 2025The Inflation Reduction Act (IRA) may be restricting Medicare Part D formularies, increasing patient costs, and stifling pharmaceutical innovation, experts warned at the Academy of Managed Care Pharmacy 2025 annual meeting.
Read More